Stockwinners Market Radar for June 12, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EDT Cathie Wood's ARK Investment buys 19K shares of PagerDuty today

19:16 EDT Bitfarms comments on Riot Platforms' attempt to disrupt strategic review process - Bitfarms Ltd. (BITF) issued the following statement in response to comments made by Riot Platforms, Inc. (RIOT) : "The Bitfarms Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. Following the receipt of multiple unsolicited expressions of interest from third parties, the Bitfarms Board formed a Special Committee comprised solely of independent directors to consider the unsolicited proposals, including an unsolicited proposal from Riot received on April 22, 2024. After carefully reviewing and evaluating Riot's proposal, the Special Committee determined that the proposal significantly undervalues Bitfarms and is not in the best interest of shareholders. The Special Committee has welcomed Riot's interest in the Company and participation in the ongoing Strategic Alternatives Review Process, including by agreeing to the standstill term proposed by Riot. Riot declined to participate in the process and instead has continued to acquire common shares of the Company in the open market in an attempt to undermine the integrity of the process and harm the interests of the Company. It is clear that Riot's interests are not aligned with those of Bitfarms shareholders, and instead of participating in the Special Committee's process in good faith, Riot is attacking Bitfarms' Board and corporate governance in an effort to push its low-ball bid and disrupt the Strategic Alternatives Review Process."

17:46 EDT RadNet CFO Mark Stolper sells $1.5M in company shares - RadNet CFO Mark Stolper disclosed the sale of 25,000 shares of company stock at $61.27 per share on June 10, for a total transactionamount of $1,531,750.

17:27 EDT Photronics places Chief Administrative Officer on leave pending internal review - The company states: "On June 11, 2024, Photronics placed Richelle E. Burr, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary, and a "named executive officer," on a paid administrative leave during the pendency of an ongoing internal review regarding certain Company transactions and other matters. During Ms. Burr's absence, her functions will be performed by other Company personnel and outside counsel."

17:23 EDT Netflix announces live hot dog eating contest with Joey Chestnut - Amanda Richards blogged for Netflix, in part: "On Sept. 2, it will be a man- eat-(hot) dog world, too. Streaming live on Netflix, 16-time hot dog- eating champion Joey Chestnut will face off against rival and six-time hot dog-eating champion Takeru Kobayashi in Chestnut vs. Kobayashi: Unfinished Beef with all-beef hot dogs. The showdown will settle a 15-year rivalry between the two competitive eaters: Will Chestnut maintain his title as the world's greatest, or will Kobayashi come in with a vengeance and regain his throne? Born and raised in San Jose, California, Chestnut holds 55 world records for competitive eating, including the world record for most hot dogs - 76 in 10 minutes, to be precise. He's also won the iconic Nathan's Famous Fourth of July International Hot Dog-Eating Contest16 times, including every year since 2016 - but on June 11, Major League Eating announced that Chestnut will be left out of the 2024 competition, citing brand exclusivity issues due to Chestnut's recent deal with competitor Impossible Foods. "Through all of my years in competitive eating, Kobayashi stands out as my fiercest rival," said Chestnut. "Competing against him pushed me to be so much better. I know that fans have waited a long time for another chapter of our rivalry and I can't wait for our massive showdown live on Netflix! It's time to give the people what they want!" Reference Link

17:08 EDT General Electric awarded $1.13B Army contract - General Electric was awarded a $1.13B firm-fixed-price contract for T700 series turbine engines. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of June 13, 2029. Army Contracting Command is the contracting activity.

17:01 EDT West Fraser Timber raises quarterly dividend to 32c per share from 30c - West Fraser Timber has declared a quarterly dividend of 32c per share on the Common shares and Class B Common shares in the capital of the company, payable on July 12, 2024 to shareholders of record on June 26, 2024. The quarterly dividend has been increased from the prior 30c per share in light of the share count reduction resulting from execution of recent normal course issuer bids. "We are pleased to increase our dividend this quarter," said Sean McLaren, West Fraser's President and CEO. "A sustainable quarterly dividend is a key priority within our capital allocation strategy."

16:49 EDT RTX awarded $506.7 contract from NASA for Landsat Next instruments - NASA selected Raytheon to provide three instruments and related services, with an option for one additional instrument, in support of the Landsat Next mission based at NASA's Goddard Space Flight Center in Greenbelt, Maryland. The contract includes a cost-plus-award-fee base period and a cost-plus-fixed-fee option period with a total value of $506.7M. The contractor will provide the design, engineering analyses, algorithms, fabrication, testing, delivery, and support for the Landsat Next Instruments. The work will be primarily performed at the contractor's facilities in El Segundo, California. The Landsat Next mission is a major component of NASA's Earth science portfolio, advancing Earth observing technologies, science, and applications. The Landsat Next mission is a partnership between NASA and the U.S. Geological Survey to advance Earth observing technologies, science, and applications under the Sustainable Land Imaging Program to more effectively map, monitor, and manage America's land, water, and coastal resources.

16:32 EDT Ameren granted approval for acquisition of 150 MW solar facility in Missouri - Ameren's Ameren Missouri subsidiary received approval today from the Missouri Public Service Commission to acquire a 150 MW solar facility that is currently under construction in Cass County, Illinois. The Cass County Renewable Energy Center will be used to double the size of the Renewable Solutions program. Organizations from across Missouri signed up to take part in the program's expansion. As part of the program, participating organizations will also receive renewable energy credits.The acquisition is anticipated to begin generating energy by the end of this year. The 150-MW Boomtown Renewable Energy Center under construction in White County, Illinois, will also support the Renewable Solutions program. It is scheduled to be in service by the end of this year as well.

16:32 EDT Coherent ships 300M transceivers from Malaysia facility - Coherent announced the shipment of its 300-millionth optical transceiver from its manufacturing facility in Ipoh, Malaysia.

16:30 EDT Pfizer says Phase 3 CIFFREO study did not meet primary endpoint - Pfizer announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in motor function among boys 4 to 7 years of age treated with the gene therapy compared to placebo. The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment (NSAA) at one year after treatment. Key secondary endpoints, including 10-meter run/walk velocity and time to rise from floor velocity, also did not show a significant difference between participants treated with fordadistrogene movaparvovec and placebo. The overall safety profile of fordadistrogene movaparvovec in the CIFFREO trial was manageable, with mostly mild to moderate adverse events, and treatment-related serious adverse events generally responding to clinical management. "We are extremely disappointed that these results did not demonstrate the relative improvement in motor function that we had hoped. We plan to share more detailed results from the study at upcoming medical and patient advocacy meetings, with the goal of ensuring that learnings from this trial can help improve future clinical research and development of treatment options that can improve care for boys living with Duchenne muscular dystrophy," said Dan Levy, MD, PhD, Development Head for Duchenne muscular dystrophy, Pfizer. "We are grateful for the boys, their families, advocates, and the investigators who have participated in this research and the continuing effort to advance treatment options for this debilitating disease." Pfizer will continue to closely monitor all participants enrolled in the study and is evaluating appropriate next steps for the program.

16:22 EDT Cerence names Jennifer Salinas Chief Administrative Officer, effective June 7 - Cerence announced that Jennifer Salinas, Senior Vice President & General Counsel, has been promoted to the newly created role of Executive Vice President & Chief Administrative Officer, effective June 7...Ms. Salinas has served as Senior Vice President & General Counsel of Cerence since April 2022. Prior to Cerence, she was Head of Litigation at Lenovo, the largest PC company worldwide, and General Counsel of the Infrastructure Solutions Group, a $7 billion Lenovo business unit. Her extensive, more than 25-year background also includes ten years as a Partner at several prominent law firms. Ms. Salinas is the former President of the Hispanic National Bar Association and has received numerous awards and recognitions throughout her career.

16:20 EDT Broadcom jumps 9% to $134.40 after Q2 results beat estimates

16:18 EDT Broadcom: 10-for-1 forward stock split expected to commence on July 15 - "The ten-for-one forward stock split will be effected through the filing of an amendment to Broadcom's Amended and Restated Certificate of Incorporation that will proportionately increase the authorized shares of common stock. Our stockholders of record after the close of market on July 11, 2024 will receive an additional nine shares of common stock for each share held after the close of market on July 12, 2024. At market open on July 15, 2024, trading is expected to commence on a split-adjusted basis."

16:16 EDT W. R. Berkley raises quarterly dividend by 9% to 12c per share - The first regular quarterly dividend at the new rate of 12 cents per share will be paid on June 28, 2024 to stockholders of record at the close of business on June 24, 2024.

16:15 EDT Fluxx enlists Domo to bring data-driven insights to grantmaking - The company states: "Domo announced that the leading cloud-based grants management solution, Fluxx, uses Domo to streamline intelligence and provide more value to its customers. More than 400 world-class foundations and government organizations use Fluxx, including 10 of the top 20 grantmakers, giving more than $15 billion and impacting more than 150,000 non-profits annually. Fluxx used Domo Everywhere to build a new, add-on solution called 'Grantelligence' that the company sells to users of its core product, creating a new revenue stream. Grantelligence delivers pre-built, customizable, grantmaking-specific datasets and dashboards that make it easy for customers to take the next step in their reporting journey. When Fluxx released Grantelligence to customers in 2023, it became one of the company's fastest-selling products ever. Out of the gate, 30% of Fluxx's beta testers purchased Grantelligence, and word quickly spread to other customers who asked to try the solution. Today, 50% of new Fluxx customers include Grantelligence in their initial purchase."

16:10 EDT Catcha Investment holders approve business combination with Crown - Catcha Investment announced that shareholders of record as of January 16, approved the previously proposed business combination with Crown LNG Holdings or Crown, a leading provider of LNG liquefaction and regasification terminal technologies for harsh weather locations. The full results of the vote will be included in a Current Report on Form 8-K to be filed by Catcha with the U.S. Securities and Exchange Commission. In line with this approval, Catcha and Crown have also agreed to extend the deadline under the Business Combination Agreement until June 28th on or before which the business combination is expected to close, and the combined company's ordinary shares and warrants are expected to commence trading on the Nasdaq Capital Market under the new ticker symbols "CGBS" and "CGBSW" respectively thereafter.

16:07 EDT Torrid names Hyon Park as new COO - Torrid announced a number of executive promotions and changes: The promotion of Hyon Park to Chief Operating Officer. The promotion of Ashlee Wheeler to Chief Planning Officer. The retirement of Mark Mizicko, Chief Commercial Officer. The Company is promoting Hyon Park, Chief Technology Officer, to Chief Operating Officer, effective immediately. In addition to his responsibilities as Chief Technology Officer and Supply Chain Management, he will also have oversight of store operations. The Company is promoting Ashlee Wheeler, Senior Vice President of Company Planning & Strategy, to Chief Planning Officer, effective immediately. Mark Mizicko announced his plans to retire from Torrid, effective June 14, 2024. He will continue as a consultant for Torrid on various projects.

16:05 EDT Barinthus Biotherapeutics to prioritize VTP-300, reduce workforce by 25% - Barinthus Biotherapeutics announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease. The decision follows the interim data from the two ongoing Phase 2 clinical trials presented at the European Association for the Study of the Liver, or EASL, Congress on June 6. The data from the ongoing HBV003 and IM-PROVE II trials demonstrated VTP-300's potential to significantly reduce and maintain Hepatitis B surface antigen levels and achieve undetectable HBsAg levels in patients with CHB. Additionally, the strategic focus on Barinthus Bio's proprietary SNAP-TI platform and lead candidate VTP-1000 in celiac disease, follows encouraging pre-clinical data demonstrating mode of action and disease amelioration being observed in a number of disease models. Celiac disease is a chronic autoimmune disorder affecting approximately 1% of people in Western countries that currently has no FDA or EMA approved treatments.1 VTP-1000 aims to balance the immune response by inducing gluten-specific T regulatory cells and reducing gluten-specific T effector cell responses. Initiation of the Phase 1 clinical trial is expected in the third quarter of 2024. The development of VTP-300 in CHB and VTP-1000 in celiac disease will be prioritized and the ongoing Phase 1 clinical trial of VTP-850 in prostate cancer will be completed. The Company expects to undergo a restructuring to align resources with the streamlined pipeline, which will include a workforce reduction of approximately 25% and an estimated extension of the cash runway into the second quarter of 2026.

16:00 EDT Cara Therapeutics trading halted, news pending

15:51 EDT Project Energy Reimagined Acqutn Corp trading halted, volatility trading pause

14:20 EDT FDA grants traditional approval to Lilly's Retevmo for thyroid cancer - The Food and Drug Administration said it granted traditional approval to Eli Lilly's Retevmo for adult and pediatric patients two years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. Retevmo received accelerated approval for this indication for patients 12 years of age and older in 2020. Reference Link

13:04 EDT vTv Therapeutics trading resumes

12:59 EDT vTv Therapeutics trading halted, volatility trading pause

12:46 EDT Danone, Michelin, DMC, Credit Agricole create Biotech Open Platform - Danone (DANOY), Michelin (MGDDY), DMC Biotechnologies and and Credit Agricole Centre France (CRARY) have agreed to create the Biotech Open Platform "to bolster the development of advanced fermentation processes, particularly precision fermentation, on a larger scale." Danone said in a statement, "Precision fermentation is a revolutionary biotechnological process to produce bio-based materials and ingredients. With an investment of over 16 million euro in the first phase, the industrial and technological platform will be located in Clermont-Ferrand within the Parc Cataroux Center for Sustainable Materials, an innovation accelerator supported by Michelin." Reference Link

12:04 EDT Li-Cycle rises 13.6% - Li-Cycle is up 13.6%, or 41c to $3.38.

12:02 EDT Desktop Metal falls -7.3% - Desktop Metal is down -7.3%, or -33c to $4.13.

12:00 EDT ZKH Group falls -58.4% - ZKH Group is down -58.4%, or -$7.89 to $5.63.

11:21 EDT WisdomTree stockholders elect all nine of company's director nominees - WisdomTree announced the preliminary voting results of its 2024 Annual Meeting of Stockholders. Based on the preliminary voting results provided by the Company's proxy solicitor, stockholders have chosen to elect ALL nine of WisdomTree's nominees to the Company's Board of Directors: Lynn Blake, Anthony Bossone, Smita Conjeevaram, Rilla Delorier, Daniela Mielke, Shamla Naidoo, Win Neuger, Tonia Pankopf and Jonathan Steinberg. Stockholders have also preliminarily accepted all other proposals, including say-on-pay, one-year frequency for say-on-pay, the ratification of the appointment of the Company's auditor and the ratification of the extension of the Company's stockholder rights plan. The preliminary vote count is subject to certification by the independent inspector of election.

10:48 EDT Cadence Design announces ongoing collaboration with Samsung Foundry - Cadence Design Systems announced a broad collaboration with Samsung Foundry that includes technology advancements to accelerate design for AI and 3D-IC semiconductors, including on Samsung Foundry's most advanced gate-all-around nodes. The ongoing collaboration between Cadence and Samsung significantly advances system and semiconductor development for the industry's most demanding applications, including AI, automotive, aerospace, hyperscale computing and mobile. Through this close collaboration, Cadence and Samsung have demonstrated the following: Cadence.AI enables lower leakage power and development of SF2 GAA test chips: Cadence, in close collaboration with Samsung Foundry, has leveraged the Cadence Cerebrus Intelligent Chip Explorer and its AI technology in both DTCO and implementation to minimize leakage power on their SF2 GAA platform. Compared to the best-performing baseline flow, the Cadence.AI result achieved a more than 10% reduction in leakage power. As part of this ongoing collaboration, a mutual customer is actively involved in the development of a test chip using Cadence.AI for an SF2 design. Cadence backside implementation flow certified for Samsung Foundry SF2: As a result of extensive collaboration between Cadence and Samsung Foundry, a complete Cadence backside implementation flow has been certified for the SF2 node to accelerate the development of advanced designs. The full Cadence RTL-to-GDS flow, including the Genus Synthesis Solution, Innovus Implementation System, Quantus Extraction Solution, Pegasus Verification System, Voltus IC Power Integrity Solution and Tempus Timing Signoff Solution has been enhanced to support backside implementation requirements such as backside routing, nano TSV insertion, placement and optimization, signoff parasitic extraction, timing and IR analysis, and DRC. The Cadence backside implementation flow has been validated with a successful Samsung SF2 test chip, demonstrating the flow is ready for use. Cadence has collaborated with Samsung Foundry to enable solutions for Samsung Foundry's multi-die offerings: The Cadence Integrity 3D-IC platform is enabled for all of Samsung's multi-die integration offerings, and its early analysis and package awareness features are now compliant with Samsung's 3DCODE 2.0 version. In addition, Cadence and Samsung have expanded the multi-die collaboration by enabling differentiating technologies like thermal warpage analysis using the Cadence Celsius Studio and system-level LVS with Cadence Pegasus Verification System. Cadence is also supporting Samsung with a package PDK that reduces design time with the Allegro X system. Combined with the Integrity 3D-IC platform, it optimizes the package design flow. Cadence.AI's Virtuoso Studio flow successfully deployed for analog circuit process migration: Purpose-based instance mapping in the AI-powered Virtuoso Studio provided rapid retargeting of the schematics, while circuit optimization in Virtuoso Studio's Advanced Optimization Platform helped Samsung achieve a 10X improvement in turnaround time when migrating a 100MHz oscillator design from 14nm to 8nm. In addition, a FinFET-to-GAA analog design migration reference flow is available for joint customers, with successful experimental results.

10:33 EDT Caterpillar boosts dividend 8% to $1.41, buyback by $20B to $21.8B - Caterpillar said its board voted to raise the quarterly dividend by 11c, an 8% increase, to $1.41 per share of common stock, payable August 20, to shareholders of record at the close of business on July 22. The board also added $20B to its current share repurchase authorization, which was launched in 2022 with no expiration date. With the new authorization, Caterpillar may repurchase up to $21.8B of its common stock. Caterpillar said it expects to continue to return substantially all Machinery, Energy & Transportation free cash flow to shareholders over time through dividends and share repurchases. "We continue to generate robust ME&T free cash flow through the execution of our enterprise strategy for long-term profitable growth," said Caterpillar Chairman and CEO Jim Umpleby. "Our strong financial performance supports increasing our quarterly dividend and share repurchase authorization, which aligns with our commitment to return substantially all ME&T free cash flow to shareholders over time."

10:20 EDT ZKH Group Ltd (ADR) trading halted, volatility trading pause

10:04 EDT RTX's Blue Canyon selected by NASA to provide spacecraft buses - RTX's Blue Canyon Technologies, was selected to build two 12U CubeSat buses for NASA's PolSIR mission, which will study ice clouds that form at high altitudes throughout tropical and sub-tropical regions. In addition to designing and manufacturing the bus platforms, Blue Canyon will also provide mission operations services. The PolSIR instrument -Polarized Submillimeter Ice-cloud Radiometer- will observe the full diurnal cycle of high-altitude ice clouds to improve climate forecasts and provide climate models with important insights on how Earth's atmosphere will change in the future.

10:03 EDT Barnes & Noble Education rises 7694.3% - Barnes & Noble Education is up 7694.3%, or $7.26 to $7.35.

10:02 EDT ZKH Group falls -7.2% - ZKH Group is down -7.2%, or -97c to $12.55.

10:00 EDT Amphenol falls -49.8% - Amphenol is down -49.8%, or -$66.94 to $67.48.

09:51 EDT New Oriental Education falls -4.8% - New Oriental Education is down -4.8%, or -$3.69 to $72.50.

09:49 EDT Sunnova Energy rises 10.7% - Sunnova Energy is up 10.7%, or 57c to $5.89.

09:47 EDT Rentokil Initial rises 15.3% - Rentokil Initial is up 15.3%, or $4.12 to $31.04.

09:42 EDT Blue Star Foods regains compliance with Nasdaq - Blue Star Foods announced that on June 11, 2024 it received a letter from the Nasdaq Hearings Panel indicating that the Company demonstrated compliance with the bid price requirement in Listing Rule 5550(a)(2) and the minimum stockholders' equity requirement in Listing Rule 5550(b)(1). Additionally, the Company will be subject to a Discretionary Panel Monitor for a period of one year, until June 11, 2025. If the Company fails to maintain compliance with any continued listing requirement during the one-year monitoring period, the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable.

09:38 EDT Barnes & Noble Education trading halted, volatility trading pause

09:32 EDT Nektar: NKTR-0165 shows selective enhancement of treg cell function in study - Nektar Therapeutics announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European Alliance of Associations for Rheumatology 2024 Congress. NKTR-0165 is a novel, first-in-class tumor necrosis factor receptor 2 agonist and bivalent antibody designed to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling. TNFR2 signaling has been shown to be an important gatekeeper of inflammation and its absence or deficit is associated with a broad range of autoimmune diseases. TNFR2 is highly expressed on Tregs, neuronal cells and endothelial cells and has been shown to potentiate the suppressive effects and overall functional properties of regulatory T cells. "The preclinical data presented at EULAR show that NKTR-0165 is a unique antibody that selectively binds to TNFR2 on Tregs to enhance its immunosuppressive activities, and could potentially become a first-in-class treatment for various autoimmune diseases, including ulcerative colitis and vitiligo," said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Research & Development Officer at Nektar. "By selectively binding to TNFR2, NKTR-0165 upregulates expression of proteins that are critical to Treg proliferation and function. Animal models show that NKTR-0165 reduces inflammation through the selective enhancement of Treg cell function via TNFR2 agonism. These data demonstrate a unique and differentiated profile for this bivalent antibody in the field of TNFR2 agonists." NKTR-0165 shows selective TNFR2 binding and receptor agonism in human Tregs, with minimal binding and signaling activity in other TNFR2-expressing immune cells in vitro and in vivo. NKTR-0165 agonistic activity enhances Treg lineage stabilization and upregulates expression of proteins involved in Treg proliferation and function. NKTR-0165 demonstrates therapeutic efficacy in a KLH-induced delayed type hypersensitivity model in human TNFR2 knock-in mice.

09:29 EDT Element Solutions raises Q2 adjusted EBITDA view to about $135M from about $125M - As part of its FY24 guidance raise announcement yesterday, the company also raised its Q2 adjusted EBITDA view to "approximately" $135M from "approximately" $125M.

09:24 EDT National Beverage declares special cash dividend of $3.25 per share - National Beverage announced that its Board of Directors has declared a special cash dividend of $3.25 per share to shareholders of record on June 24. FIZZ will trade ex-dividend on June 24 and the payment date for this dividend will be on or before July 24. "With this special dividend, our twelfth in the past 20 years, FIZZ holders will have received $16.53 per share, or over $1.5 B ," stated a company spokesperson. "Our consistent performance in unusual circumstances and excellent, innovative products continue to generate superior operating cash flows while maintaining one of the industry's strongest balance sheets. We most recently reported eleven consecutive quarters of record sales coupled with improving gross profits and operating income."

09:20 EDT Maximus announces $200M expansion to share repurchase program - Maximus announced that its board of directors has authorized an expansion to the purchase program for Maximus common stock of up to an aggregate of $200M. This includes the approximately $6M of remaining availability under the existing stock purchase program. Maximus intends to purchase shares opportunistically at prevailing market prices in the open market, or in privately negotiated transactions, with the amount and timing of purchases depending on market conditions, corporate needs, and other factors.

09:12 EDT American Express CFO 'disappointed' agreement can't be reached with eBay - Says disagreement with eBay a rare occurrence.

09:09 EDT Core & Main announces $500M share repurchase authorization - Core & Main announced that its board of directors has authorized the repurchase of up to $500M of the Company's outstanding shares of Class A common stock. "We remain confident in our ability to grow faster than our end markets, while expanding profitability and generating strong cash flow. Today's Repurchase Authorization displays our commitment to returning capital to shareholders. Our expectation of strong cash generation will allow us to continue investing in growth, both organically and inorganically, while returning capital to shareholders to compound long-term value creation," said Steve LeClair, chair and CEO of Core & Main. .

09:07 EDT Varonis announces new capabilities to strengthen data security posture - Varonis Systems announced new capabilities to automatically and continuously strengthen data security posture and prevent data breaches across AWS. Cloud providers give organizations the flexibility and power to create and proliferate cloud data workloads faster than ever. But flexibility breeds risk. Understaffed security teams are inundated with data security issues that must be reviewed and resolved one by one. This slow and manual process creates a needlessly large vulnerability window for attackers to exploit. Varonis' new remediation capabilities create a self-securing AWS environment that keeps pace with rapid data growth and developer agility. With little to no effort, security teams can block public access to sensitive S3 buckets, remove stale users and roles, and delete inactive access keys. Varonis' intelligent automation focuses on actions with high-security value and zero business impact.

09:07 EDT Philips announces first implant of Duo Venous Stent System - Royal Philips announced the first implant of the Duo Venous Stent System, an implantable medical device indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency, following premarket approval from the U.S. Food and Drug Association .

09:05 EDT Sintx Technologies regains compliance with Nasdaq bid price requirement - SINTX Technologies announced that on June 11, 2024, the Company received formal notice from The Nasdaq Stock Market that the Company has evidenced compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Accordingly, the previously announced listing matter has been closed. The Company remains subject to a "Mandatory Panel Monitor," as that term is defined in Listing Rule 5815(d)(4)(B), for a period of one year from June 11, 2024. If, within the one-year period, the Company fails to satisfy the minimum $1.00 closing bid price threshold for 30 consecutive business days, Nasdaq will issue a delist determination rather than provide the Company with a grace period to regain compliance with the Bid Price Rule. In that event, the Company would have the opportunity to request a new hearing to address the deficiency.

09:04 EDT ADW Capital sends letter to GFL Environmental's board, management - ADW Capital Management, which owns 1,650,000 shares of GFL Environmental together with its affiliates, issued an open letter to GFL's board of directors and management team regarding opportunities to maximize value for all shareholders and reiterating its call for the Company to undertake a strategic review process. "...Not much externally has changed since we wrote to the Board roughly seven months ago in November 2023. Before an 'impatient third-party' likely leaked their interest in the Company's Environmental Solutions division or "ES", the Company's shares were trading at roughly 9.5x our estimate of 2025E EBITDA CAD - THE LARGEST DISCOUNT TO THE BROADER NORTH AMERICAN WASTE INDUSTRY SINCE THE IPO.... From recent actions, we believe the Board and management have clearly shown they are more focused on themselves and are NOT ALIGNED WITH MINORITY SHAREHOLDERS... As set forth below, we believe the sale of ES at a 14-15x EBITDA multiple,4 as rumored in the press, would have a multi-pronged benefit to the Company: By our estimates, the sale of ES will result in minimal tax leakage and leave the Company with the lowest leverage in the broader North American waste industry at roughly ~1x before capital allocation... A sale of ES would create a solid-waste 'pureplay' when paired with the Company's RNG/EPR/Tuck-in program that would likely have a better 'go forward' growth algorithm and potentially trade at a higher multiple than the Company's often mentioned pure-play peer --- Waste Connections... GFL's new business mix would be solidly US-centric and open up a path to a US domicile and listing... But most importantly, the sale of ES allows the Company to remove most, if not all, of the overhang from their lead sponsor, BC Partners, who has shown a willingness to sell the stock at basically any price / multiple of NTM EBITDA. "

09:03 EDT Precipio says pathology revenue 'heading back towards' breakeven point - Precipio provides the following update to its shareholders on various business matters. The company said, "In September of 2023, Precipio's pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the quarter. In the following quarter, as previously discussed, due to several operational issues, revenue declined below that point. We are pleased to report that the company has addressed the operational issues and as a result, pathology revenue is heading back towards its breakeven point. We anticipate that in the next quarter, Q3-2024, the pathology division will return to exceeding its breakeven point. On the products side, the company had several delays in product releases due to several technical and supply chain issues which often occur in this line of business. These hurdles have been addressed, and revenue growth is resuming. Recently, two major new customers received state regulatory approval for implementing our technology in their practice and we anticipate them going live early next quarter. These two customers are much larger than our average customer and we expect that they, along with several other customers in various onboarding stages, will provide a significant boost to product revenues and significantly advance us toward the necessary $6M annualized product revenue run rate goal that is part of our overall plan to reach profitability. As we previously mentioned, like many healthcare companies, Precipio too was impacted by the Change Healthcare hacking and subsequent freeze on cash inflow from the pathology services division. We appear to be at the tail-end of this situation, with Change Healthcare in the process of resuming normal operations. The company has taken measures to supplement its cash situation through short-term loans, both from Change Healthcare and independent sources, ensuring it has sufficient funds to continue operations. We expect a return to normal operations in Q3-2024, and to a quick return of any Change Healthcare loans. Furthermore, with the expected revenue growth discussed in the previous point, we anticipate a gradual reduction in cash burn, heading towards anticipated breakeven later in the year. The recent FDA ruling will ultimately transition Laboratory Developed Tests that are currently under the regulation of other federal and private agencies such as CLIA and COLA, to fall under the FDA's jurisdiction as FDA-approved tests. This will require filings by test manufacturers and/or laboratories to register LDTs with the FDA. Requirements will be phased in over the next 4 years...This impacts both our pathology services division and our products division as follows: Pathology services division:The FDA rule has stipulated that any tests that a lab was operating before the ruling on May 2023 are "grandfathered" into approval and do not require any additional work. This applies to all our current tests. Should Precipio's laboratory decide to add a test in the future, it will most likely add FDA-approved tests which will not place any burden on our laboratory. Therefore, the company does not expect any substantial budgetary impact to its pathology services division due to this ruling."

09:01 EDT Professional Diversity's RemoteMore launches platform to source candidates - Professional Diversity Network announced its subsidiary company, RemoteMore, unveiled a new database platform for PDN's event team. This advanced system is designed to enhance the recruitment process, providing a solution for candidate and resume management.

08:56 EDT Syra Health awarded contract with North Carolina Department of Public Safety - Syra Health announced it has been awarded a contract with the North Carolina Department of Public Safety, Division of Juvenile Justice and Delinquency Prevention to provide statewide nursing services. The contract is effective for one year, with two additional one-year renewal options. Under the contract, Syra Health will supply temporary nursing staff to Youth Development Centers and Juvenile Detention Centers across North Carolina. The roles include registered nurses, licensed practical nurses, medical technicians, and certified nursing assistants to provide for the medical needs of youth in the custody of the Department of Public Safety. The revenue generated by the contract is based on both the number of positions to be filled and the duration of each.

08:40 EDT LightPath, Maris-Tech partner for AI-ready infrared cameras - LightPath Technologies (LPTH) has, in partnership with Maris-Tech ((MTEK), integrated critical hardware and firmware necessary to support A.I. software and algorithms in all of the Company's infrared cameras, marking a significant step in the evolution of its technology. The new AI-enabled feature will be available as an option on all cameras and is referred to by name as EdgeIR.

08:38 EDT Jaguar Health to report Phase 3 OnTarget trial results on or before July 23 - Jaguar Health announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar's advancing cancer supportive care portfolio, will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis. "Patients are the heart of our mission at Jaguar," said Lisa Conte, the company's president and CEO. "The thorough and exhaustive OnTarget prophylactic protocol allowed for the inclusion of all treatment needs for participating patients with solid tumors and targeted therapy, including any supportive care. We look forward to receiving and providing the results with the anticipation we know all our stakeholders share. As with many pharmaceutical companies involved with an expansive global pivotal study, we use several third-party contractors. In order to address the complexity of OnTarget's statistical programming needs - as the trial involves multiple solid tumor types, 23 targeted therapies, six countries, daily patient-reported outcomes covering anywhere from 90 to 180 days with multiple entries a day, and concomitant medications - we retained a clinically experienced biostatistics and programming expert to review and lead the statistical programming and the implementation of the statistical analysis plan submitted to the FDA. The third-party vendors who are conducting the analysis of patient data for the OnTarget trial have identified the key necessary steps required to share results with Jaguar on or before July 23, allowing us to set a date for the findings."

08:36 EDT Surrozen publishes study in 'eLife' on the proprietary SWEETS platform - Surrozen announced publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS, Surrozen Wnt signal Enhancer Engineered for Tissue Specificity, bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications. This publication presented research that was focused on extending previous work by Surrozen scientists on fusing an RSPO2 mutant protein to an antibody that binds ASGR1 which led to hepatocyte-specific enhanced signaling, proliferation, and restored liver function in mouse models. In this publication, the authors described the development of two new ASGR bispecific antibodies which revealed distinct epitopes on both ASGR1 and ASGR2 that resulted in a robust and cell-specific Wnt-signal activation.

08:35 EDT Star Equity announces 1-for-5 reverse stock split - Star Equity Holdings announced today a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-5 and that it has filed a Certificate of Amendment of the Company's Restated Certificate of Incorporation in order to effect the Reverse Split. The Reverse Split will take effect after market close on June 14, 2024, and common shares will begin trading on a post-split basis on the Nasdaq Global Market under a new CUSIP number at the open of trading on June 17, 2024. The Company's common stock will continue to trade under the symbol "STRR".

08:34 EDT Transport, infrastructure solutions provider adopts INBS' drug screening tech - Intelligent Bio Solutions announced the addition of a major European transport and infrastructure solutions provider to its growing number of accounts. The company is using INBS' Intelligent Fingerprinting Drug Screening System to monitor fitness for duty of employees within its United Kingdom operations.The decision to integrate INBS' innovative technology into the company's operations demonstrates its commitment to employee safety and operational efficiency. Previously, it used sporadic, for-cause urine testing involving a third-party provider with a minimum two-hour call-out time. The company wanted to implement random testing on-site that was quicker and more efficient. INBS' solution facilitates in-house drug testing, ensuring greater efficiency, a safer workplace and compliance with industry standards and the company's code of conduct.

08:32 EDT Perma-fix Environmental provides further updates on Perma-FAS - Perma-Fix Environmental Services provided an update on its patent-pending new process, Perma-FAS, for the destruction of per- and polyfluoroalkyl substances, including design specifications and the Company's selection of ProcessBarron for the fabrication and assembly of its new Perma-FAS commercial unit. Mark Duff, President and CEO of Perma-Fix, commented, "We are making rapid progress on the design and fabrication of our first Perma-FAS commercial unit, which we expect to be operational later this year. Towards this end, we are delighted to partner with ProcessBarron, which brings decades of experience constructing custom-engineered industrial solutions. We believe their track record and efficiency on such projects lends itself well to our strict timelines and safety standards, given the tremendous demand we have witnessed since first announcing our new system. Our relationship with ProcessBarron leverages their decades of experience in the application of proven industrial innovations to enhance performance of our initial system, while providing access to their team of engineers for system optimization. Following startup at our first facility, this relationship provides the ability to deploy additional units at our other facilities with increased efficiency, while reducing delivery schedules to support accelerated treatment activities to address nationwide PFAS markets over the next few years."

08:32 EDT Adeia's hybrid bonding technology continues to capture attention - Adeia (ADEA) announced recent developments in hybrid bonding a technology targeted toward the future of semiconductor packaging enabling high-performance computing capabilities, like those required for AI. The company has experienced encouraging continued interest after its 2023 announcement that Kioxia Corporation and Western Digital (WDC) entered into a long-term agreement to license Adeia's semiconductor patent portfolio, including those relating to hybrid bonding.

08:31 EDT T. Rowe Price reports preliminary AUM $1.54T at May 31 - T. Rowe Price Group reported preliminary month-end assets under management of $1.54T as of May 31, 2024. Preliminary net inflows for May 2024 were $6.7B, including a large institutional fixed income inflow.

08:29 EDT Equillium to be included in the Russell Microcap Index on July 1 - Equillium announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "We're happy to be joining the Russell Microcap Index, paving the way for potential inclusion in a large number of funds that aim to mimic and benchmark the Russell indices," said Bruce Steel, chief executive officer at Equillium. "This increased exposure can also highlight our recent Phase 2 alopecia areata data - indicating EQ101 was well-tolerated and clinically active - that will inform future development, as well as our partnership with Ono Pharmaceutical where we expect to delivery our final data package during the third quarter of this year."

08:23 EDT Amdocs announces AT&T Mexico competes cloud transformation - Amdocs (DOX) announced that AT&T Mexico (T) has completed a major cloud transformation of its Amdocs Customer Experience Suite systems to Oracle Cloud Infrastructure (ORCL). By placing its Amdocs systems on OCI, AT&T Mexico will benefit from flexibility and capacity growth, reduced operational costs, and state-of-the art cloud infrastructure that will allow AT&T Mexico to continue implementing its unique vision in the Mexican marketplace, providing superior services and customer experience.

08:18 EDT Archer completes Midnight's transition flight with flying speed of 100+ mph - Archer Aviation announced that on June 8th its Midnight aircraft successfully completed transition flying at a speed of 100+ mph. Archer has now achieved transition with two different full-scale eVTOL aircraft. Transition is well known in the industry as a very difficult milestone few companies have reached. At ~6,500 lbs, Midnight is believed to be one of the largest eVTOL aircraft to complete transition, which is critical to being able to carry commercially viable passenger payloads. A transition flight occurs when the aircraft takes off vertically like a helicopter, accelerates forward, transitions from thrust-borne to wing-borne flight like an airplane with tilt propellers forward before decelerating and landing vertically. Click here to view a full video of the transition flight. "Transitioning two generations of full-scale eVTOL aircraft in less than 2 years is another remarkable achievement for Archer's team. This shows we continue to successfully execute against our plan to create the most efficient path to market with an aircraft that is designed for certification and to be manufactured efficiently at scale," said Adam Goldstein, Archer's Founder and CEO.

08:17 EDT TMC, SGS produce cobalt sulfate from deep-seafloor polymetallic nodules - TMC the metals company, has produced the world's first cobalt sulfate derived exclusively from seafloor polymetallic nodules. The cobalt sulfate was generated during bench-scale testing of TMC's hydrometallurgical flowsheet design with SGS Canada. The test work was carried out at SGS' Metallurgical Centre of Excellence testing facility in Lakefield, Ontario. Based on samples of nickel-cobalt-copper matte first produced by TMC in 2021, the Extractive Metallurgy team at SGS tested TMC's efficient flowsheet to process high-grade nickel-copper-cobalt matte directly to high-purity cobalt sulfate without making cobalt metal, while producing fertilizer byproducts instead of solid waste or tailings. This milestone follows last month's successful production of nickel sulfate, a key raw material input used in the production of energy-dense electric vehicle batteries.

08:15 EDT Huge says 25% of projects contain AI components - Huge announced that for the first time in the company's history, 25 percent of its projects contain AI components. Recent work includes projects with Google, Hublot and newly announced client, Darling Ingredients. Huge's growing AI project roster underscores the company's commitment to shaping the future of intelligent experiences. By leveraging AI and other emerging technologies, Huge is creating personalized, contextual and intent-aware digital experiences. Newly announced IX work includes: Darling Ingredients: Huge launched a new flagship digital experience using a wealth of imagery created entirely by AI to deliver both production efficiencies and brand elevation. Google: Huge is enhancing Google's Keyword blog and news site with AI to make Google product news and tips more accessible, saving time and adding value for readers. Hublot: Huge is developing the first "Luxury AI" prototype to deliver highly personalized, white-glove experiences aimed at increasing customer lifetime value.

08:14 EDT Maris-Tech collaborates with LightPath for AI-ready infrared cameras - Maris-Tech Ltd. (MTEK) announced a collaboration with LightPath's (LPTH) in which Maris-tech integrated critical firmware and hardware to support AI algorithms embedded in LightPath's infrared cameras, completing a significant step in the evolution of LightPath's technology with the support of AI accelerated hardware, software and algorithms in all its infrared cameras. The new AI-enabled feature will be available as an option on all of LightPath's cameras and is referred to as EdgeIR.

08:14 EDT Fangdd Network announces Xie resigned from board, Luo to succeed - Fangdd Network Group announced that the Company's board of directors has appointed Jun Luo as a director of the Company, the chairman of the Nominating and Corporate Governance Committee, a member of the Compensation Committee, and a member of the Audit Committee, to succeed Zhen Xie, who has resigned from these positions for personal reasons. These Board and committee changes became effective as of June 10, 2024. Luo is currently the co-vice chairman of the board of directors and the chief executive officer of Kaisa Health Group Holdings

08:12 EDT Well+Good, Philiops Sonicare announce partnership - Well+Good in partnership with Philips Sonicare announced the launch of Self-Care Switch Up, a content series that celebrates oral care as a critical element of self-care. Philips Sonicare and Well+Good are encouraging people to make the Sonicare Switch - switching from their manual toothbrush to elevate their daily routines with a Philips Sonicare power toothbrush.

08:10 EDT Smith-Midland Corp secures $7.5M noise wall contract - Smith-Midland Corporation has been awarded a new $7.5 million precast concrete noise wall contract for a Georgia Department of Transportation project.

08:09 EDT PDS Biotechnology provides update from ongoing VERSATILE-002 Phase 2 trial - PDS Biotechnology provided a data update from its ongoing VERSATILE-002 Phase 2 clinical trial. VERSATILE-002 is evaluating Versamune HPV + KEYTRUDA in patients with HPV16-positive head and neck squamous cell cancer. The Kaplan-Meier analysis captures the survival data for immune checkpoint inhibitor naive patients from the ongoing VERSATILE-002 Phase 2 clinical trial. All patients whose data are reported in the Kaplan-Meier analysis are properly censored to confirm their follow-up and survival status. Based on a data cut as of May 17, 2024, the updated survival data for the cohort of ICI naive patients after an additional follow-up of approximately 6 months in the VERSATILE-02 Phase 2 clinical trial with a total of 53 enrolled patients was as follows: mOS is 30 months, consistent with data presented at the Company's Key Opinion Leader event on May 9, 2024, which was based on a data cut as of November 30, 2023. 27 of the censored patients remained alive and were awaiting their next clinical assessment, 6 censored patients had withdrawn consent for further follow-up, and 2 patients had been lost to follow-up, and 18 patients had died. The lower limit of the 95% confidence interval is 19.7 months, and the upper limit is not yet estimable, as the majority of the patients continue to be followed for survival. Full data from the May 17, 2024 data cut are expected to be announced in Q3 2024.

08:08 EDT Simulations Plus acquires Pro-ficiency for $100M in cash - Simulations Plus announced the acquisition of Pro-ficiency and its subsidiaries. Simulations Plus acquired Pro-ficiency from QHP Capital and Pro-ficiency's minority shareholders for approximately $100M in cash. The transaction expands Simulations Plus' presence across the drug development continuum from establishing pre-clinical protocols to product commercialization, providing pharmaceutical and biotech companies with an end-to-end offering that now includes clinical trial operations, medical affairs and commercial market launches. Pro-ficiency's suite of software and services, developed with AI technologies, is a highly complementary and synergistic addition to Simulations Plus' platform by expanding its capabilities to enhance clinical trial and launch training, data analytics and outcomes. The transaction is being funded from existing cash and investment resources. "With approximately $119 million in cash and investments available, this acquisition allows us to utilize the capital from our August 2020 follow-on public offering," said Will Frederick, Chief Financial Officer and Chief Operating Officer of Simulations Plus. "Following the acquisition, we remain well-capitalized with no debt, have strong free cash flow, and will continue our capital allocation strategy and corporate development initiative to seek additional opportunities for strategic acquisitions, investments, and partnerships."

08:06 EDT Fox Corp. announces newly expanded partnership with FreeWheel - Fox Corp. announced that through its newly expanded partnership with FreeWheel, a global technology platform for the television advertising industry, it will expand its dynamic ad insertion capabilities and rollout new co-developed targeting technology. FreeWheel will also become Fox's primary ad serving partner across the entire One Fox enterprise. FreeWheel's technology will now power Fox's ability to offer dynamic ad insertion in College Football, allowing advertisers to purchase more premium live sports inventory from Fox while also incorporating a variety of features to provide an optimal viewing experience for audiences. Fox's AdRise and FreeWheel have also partnered to build technology that can enrich an ad opportunity with contextual signals ranging from specific player or team information to the type of play or score happening in the live game. This further allows advertisers to purchase One Fox inventory in high attention moments where audiences are paying closer attention to the onscreen action. The move comes as Fox furthers its shift toward automated forms of ad transactions. FreeWheel will utilize capabilities across its portfolio, including Beeswax, to create a unified pool of premium video ad inventory across the entire One Fox portfolio that can be more directly available to marketers using FreeWheel's technology. This long-term deal expands on FreeWheel's previous relationship with Fox. In November 2022, Fox Corporation announced that it had tapped FreeWheel to power its One FOX video inventory across the company's leading entertainment, sports, streaming and news portfolio.

08:05 EDT Quoin Pharmaceuticals signs research agreement with University College Cork - Quoin Pharmaceuticals has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin as potential treatments for a number of rare and orphan diseases for which there are currently no approved therapies or cures. UCC will apply its proprietary dissolvable microneedle delivery technology along with other formulation approaches to optimize the local delivery of rapamycin and potentially enhance its therapeutic effectiveness as a potential treatment for several pre-identified clinical targets. Under the terms of the agreement, Quoin will fund a research program at UCC to investigate the development of a number of topical rapamycin formulations for future development as potential treatments for several rare and orphan diseases, where it is believed that the drug's mechanism of action may provide for clinical efficacy in these settings. Following completion of the research program, Quoin will have the option to advance the clinical development of rapamycin formulations developed by UCC. The terms of the agreement do not require Quoin to pay any upfront license or milestone fees or any royalties based on future product sales.

08:03 EDT GSK, Ochre Bio enter multi-year data license agreement - Ochre Bio, a pioneer in chronic liver disease medicine development, has announced the start of a multi-year data license agreement with GSK. The partnership will provide GSK with access to Ochre Bio's computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. The collaboration will enable Ochre Bio and GSK to deepen the understanding of liver biology, aligned with GSK's disease area focus in hepatology, with the aim to further prioritize and accelerate development of medicines to address liver disease. The data will be used by both Ochre Bio and GSK to build better AI models, allowing for fewer, but more precise experiments to aid in target choice.

08:02 EDT Phunware to attend HITEC to showcase hospitality solution - Phunware will attend the Hospitality Industry Technology Exposition and Conference, HITEC, the world's largest and oldest hospitality technology conference, from June 24-27 in Charlotte. Members of Phunware's executive and sales teams will be onsite and exhibiting its leading hospitality solution at the Charlotte Convention Center Exhibit Hall, Booth #3955. "We're thrilled to showcase the transformative power of our hospitality solutions at HITEC this year, as we continue to drive growth and innovation for our customers," said Mike Snavely, CEO of Phunware. "Looking across our portfolio, our hospitality customers are generating six-to-seven figures of annual ancillary revenue and app store ratings of 4.9+. All of this while providing an exceptional guest experience that generates positive online reviews for the property."

07:43 EDT Casey's General Stores raises quarterly dividend by 16% to 50c per share - As part of its Q4 earnings yesterday, the company stated: "At its June meeting, the Board of Directors voted to increase the quarterly dividend by 16% to $0.50 per share, which is the 25th consecutive year increasing the dividend. The dividend is payable August 15, 2024, to shareholders of record on August 1, 2024."

07:36 EDT Bombardier unveils newly branded Global 7500, Challenger 3500 aircraft - Bombardier announced that its record-setting Global 7500 and best-selling Challenger 3500 aircraft will be on display during the Catarina Aviation Show on June 13-15 in Sao Paulo, Brazil, revealing the uncompromising attributes of these impressive business jets for clients in the region. The Global 7500 provides exceptionally fast and smooth flights for long missions, connecting clients in Sao Paulo directly to key destinations such as Dubai, London, Tel Aviv, New York and Geneva. The category-leading Challenger 3500 flies comfortable, seamless journeys from Sao Paulo to San Juan and Panama City, as well as to most destinations in Europe with a single stop. Customers in the region also benefit from piece of mind through Bombardier's standard-setting services network, including dedicated Authorized Service Facility MAGA Aviation at the Catarina Airport in Sao Paulo which provides line maintenance, Bombardier parts, and tooling for all Learjet, Challenger and Global aircraft.

07:35 EDT Vivos closes $7.5M investment, launches marketing, distribution alliance - Vivos Therapeutics announced the execution of a strategic marketing and distribution alliance with an operator of multiple sleep testing and treatment centers in Colorado. This alliance, which Vivos hopes will be the first of a series of similar alliances across the country, marks an important pivot in Vivos' marketing and distribution model for its cutting edge OSA appliances. Vivos also announced the related closing of a $7.5 million equity growth investment from New Seneca Partners, a leading North American private equity sponsor based in Southfield, Michigan. This investment materially bolsters Vivos' cash on hand and stockholders' equity and will facilitate the launch of the new strategic alliance and potentially other similar alliances, which is expected to positively impact Vivos' revenue growth. Under the new alliance, Vivos and the sleep center operator have agreed to collaborate to offer OSA patients a full spectrum of evidence-based treatments such as continuous positive airway pressure machines, and Vivos' advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods offered by Vivos. The program will commence in two existing sleep treatment centers in Colorado, with operations expected to begin in July 2024. Vivos' sleep center collaborator is presently rebranding its name in light of the new alliance, and Vivos expects to be able to share further details in the near future. The $7.5 million private placement investment by Seneca into Vivos consists of 3,220,266 shares of common stock and a five-year common stock warrant to purchase an aggregate of up to 3,220,266 shares of common stock. Seneca paid a purchase price of $2.329 for each share and associated warrant, with such price being "at the market" for purposes of Nasdaq Stock Market rules. The warrants are exercisable for $2.204 per share. No placement agent was utilized in connection with the financing. Seneca has also been provided with Vivos Board of Directors observation rights. The new marketing and distribution strategic alliance is based on a revenue-sharing model between Vivos and the sleep center operator. Subject to certain conditions, Seneca will participate in Vivos' net cash flow allocation from the alliance up to an agreed-upon amount as partial consideration for its management advisory services to Vivos.

07:32 EDT Kelly Services completes sale of Ayers Group - Kelly has completed the sale of Ayers Group, a division of KellyOCG, to Keystone Partners, a Silver Oak Services Partners LLC portfolio company. Ayers Group provides outplacement, executive coaching, and leadership development solutions to employers across a wide range of industries. Terms of the sale were not disclosed. The sale of Ayers Group sharpens KellyOCG's focus on global recruitment process outsourcing and managed service provider solutions. The transaction also unlocks incremental capital to redeploy toward Kelly's specialty strategy.

07:32 EDT Keystone Partners acquires The Ayers Group from Kelly Services, no terms - Keystone Partners announced that it has acquired The Ayers Group, a company involved in executive coaching, leadership development and outplacement services, from Kelly Services. This strategic acquisition further broadens Keystone's capacity to deliver exceptional career management and leadership transformation solutions in the New York metropolitan area.

07:31 EDT Bread Financial reports May net loss rate 8.8% vs. 8.4% last year - Reports end-of-period credit and other loans $17.85B vs $18.08B last year. Reports delinquency rate of 5.9% vs 5.5% last year

07:25 EDT Matador announces Ameredev unit acquisition, consisting of $1.91B cash payment - Matador Resources announced that a wholly-owned subsidiary of Matador has entered into a definitive agreement to acquire a subsidiary of Ameredev II Parent or Ameredev, including certain oil and natural gas producing properties and undeveloped acreage located in Lea County, New Mexico and Loving and Winkler Counties, Texas . The Ameredev Acquisition also includes an approximate 19% stake in Pinon Midstream, LLC Pinon , which has midstream assets in southern Lea County, New Mexico. The consideration for the Ameredev Acquisition will consist of a cash payment of $1.905 B, subject to customary closing adjustments. Ameredev is a portfolio company of EnCap Investments. The Ameredev Acquisition is subject to customary closing conditions and is expected to close late in the third quarter of 2024 with an effective date of June 1. Joseph Wm. Foran, Matador's Founder, Chairman and CEO, commented, "Matador is very excited to work with EnCap again on this strategic bolt-on opportunity . As with the successful Advance Energy deal we completed in April of 2023, we view the Ameredev transaction as another unique opportunity to work with EnCap and another value-creating opportunity for Matador and its shareholders. We evaluated this opportunity based on the high rock quality, the strong existing production and cash flow profile, the significant reserves additions, the high-quality inventory, the strategic fit within our existing portfolio of properties and the expansion of our midstream footprint with an ownership interest in Pinon. The equity and debt securities offerings and the revolving credit facility amendment we completed earlier this year, together with our historical balance sheet conservatism, have provided Matador with the opportunity to acquire these high-quality assets and continue Matador's consistent history of profitable growth at a measured pace."

07:09 EDT Regenxbio promotes Curran Simpson to CEO - Regenxbio announced that Curran Simpson, COO, has been appointed as President, CEO and a member of the Board of Directors, effective July 1. Co-Founder Kenneth T. Mills will step down as President and CEO following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tasse has been appointed as REGENXBIO's Lead Independent Director, a role previously held by Jerry Karabelas, Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board. Simpson is a seasoned biopharmaceuticals leader with over 35 years of industry experience. As the COO at REGENXBIO since January 2023, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Simpson joined REGENXBIO in 2015 and served as the Company's Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim COO at GlaxoSmithKline. Simpson earlier served as interim CEO at Human Genome Sciences, where he led the integration of HGS into GSK.

07:08 EDT Vertex acquires AI tax capabilities from Ryan, terms not disclosed - Vertex announced the acquisition of tax-specific AI capabilities from Ryan, LLC, a tax services and software firm, designed to more effectively manage the complexity of tax mapping. Financial terms of the transaction were not disclosed. The categorization of products for taxability is a manual and time-consuming process that is critical for achieving enhanced tax accuracy, especially for high-volume businesses that must manage indirect tax compliance globally, at scale. The acquisition will accelerate Vertex's AI innovation strategy to help global companies manage tax complexity with greater speed and scale. The new Vertex AI capabilities leverage proprietary and private Large Language Models to deliver Generative Pre-Trained Transformer capabilities combined with "human in the loop" tax expertise to maintain a strong control framework to increase the accuracy for tax compliance. Proprietary LLMs allow Vertex to deliver trusted AI that achieves enhanced accuracy without aggregating, sharing or mining customer data like other approaches. This enables tax teams to realize the benefits of AI technologies while maintaining control of their data. Vertex's tax-intelligent approach combines advanced AI capabilities with automation that identifies when human intervention is necessary. This enables tax teams to achieve greater speed, efficiency and the highest levels of tax accuracy.

07:06 EDT Taysha Gene Therapies to present clinical data from REVEAL Phase 1/2 trials - Taysha Gene Therapies will host a webcast on Tuesday, June 18, 2024, to discuss new clinical data from the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome, as well as provide a program update. The data will also be presented at the 2024 International Rett Syndrome Foundation Rett Syndrome Scientific Meeting taking place in Westminster, Colo., June 18-19, 2024.

07:05 EDT Ero Copper's Tucuma project awarded operational license - Ero Copper announces that it has received the Operational License for the Tucuma Project - the last remaining permitting milestone for commercial operation. With physical completion at approximately 99%, commissioning well advanced, and over 90% of the operational staff hired and trained, first concentrate continues to be expected early in the third quarter of 2024. The total direct capital cost estimate for Project completion remains unchanged at approximately $310 million.

07:03 EDT Bread Financial to provide dual credit card program for Saks Fifth Avenue - Bread Financial announced a multi-year, multi-payments product agreement with Saks Fifth Avenue. The existing Saks World Elite Mastercard Credit Card and the Saks Credit Card will be issued and supported by Comenity Capital Bank, a subsidiary of Bread Financial, beginning in August 2024. Additionally, Bread Financial signed a definitive agreement to transition the existing Saks Fifth Avenue credit card portfolio from another issuer. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. Cardmembers can use their credit cards online and at all Saks Fifth Avenue and Saks OFF 5TH locations and earn two to six points per dollar spent using their credit card, based on the tier level.1 Saks World Elite Mastercard cardmembers can also earn two points per $1 on purchases outside of Saks Fifth Avenue and Saks OFF 5TH everywhere Mastercard is accepted.2 Points are redeemable for SaksFirst Gift Cards.

07:03 EDT Dorman Products announces opening of drive shaft manufacturing facility - Dorman Products announces the grand opening of a new drive shaft manufacturing facility in Virginia Beach, VA. A ribbon cutting ceremony to celebrate the launch of the expansive factory at 464 Progress Lane is scheduled for Wednesday, June 12th. The facility joins existing Dorman sites in Reno, NV and Portland, TN that also design, manufacture and distribute the company's 3,600+ precision steel and aluminum driveshafts and related driveline components in North America. At 100,000 square feet, the new plant is five times the size of the company's former Virginia Beach site on Squadron Court.

07:02 EDT Avidity Biosciences announces data from Phase 1/2 FORTITUDE trial - Avidity Biosciences announced positive initial AOC 1020 data from the Phase 1/2 FORTITUDE trial demonstrating unprecedented and consistent reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy, or FSHD. Avidity plans to accelerate initiation of registrational cohorts in the FORTITUDE study. Avidity also announced delpacibart braxlosiran as the approved international nonproprietary name of AOC 1020, abbreviated as del-brax. Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD, which is caused by the abnormal expression of a gene called double homeobox 4 or DUX4. FSHD is a rare, hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. Currently, there are no approved therapies for the treatment of FSHD. "As the first therapy to directly target DUX4, it is very encouraging to see that the del-brax data demonstrate consistent reductions in DUX4 regulated genes and provided trends of functional improvement in patients with FSHD at the four-month timepoint. These early data would support the notion that del-brax has the potential to change the course of disease for people living with FSHD," said Jeffrey M. Statland, Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator. "Early data showing trends in del-brax to improve muscle strength and function are very encouraging for patients with FSHD who are in need of treatments to prevent the muscle weakness and disability that is associated with this relentlessly, progressive disease." The AOC 1020 initial data will be highlighted in an oral presentation at the 31st Annual FSHD Society International Research Congress, being held June 13-14, 2024, in Denver, Colorado.

07:01 EDT Dianthus announces FDA clearance to initiate Phase 2 trial of DNTH103 - Dianthus Therapeutics announced U.S. Food and Drug Administration, FDA, clearance of its Phase 2 Investigational New Drug, IND, application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy, MMN. "Pre-clinical and clinical evidence support the classical pathway's role in the pathology seen in MMN," said Simrat Randhawa, MD, Chief Medical Officer of Dianthus Therapeutics. "DNTH103 is a potent and highly selective inhibitor of active C1s resulting in classical pathway inhibition, without inhibiting the alternative and lectin pathways that are critical in the defense against infection. The Dianthus medical team and our MMN steering committee are excited to investigate the potential benefits DNTH103 may bring to MMN patients."

06:52 EDT Figs appoints Sarah Oughtred as CFO - FIGS announced the appointment of Sarah Oughtred as the Company's new CFO. To facilitate a smooth transition, Ms. Oughtred will join FIGS on July 29, 2024, and will become FIGS' CFO, effective August 9. Oughtred will lead all aspects of finance, including FP&A and accounting, and will also lead data analytics. Oughtred spent almost 17 years at lululemon, where she served in finance leadership roles of increasing responsibility, including Senior Vice President, Financial Planning & Analysis since 2021. In that role, Oughtred led a global team of over 100 finance team members, served as a key partner to the Senior Executive Team, drove the financial component of strategic and operational planning, and led the company's annual and quarterly financial planning and earnings processes. Over her tenure at lululemon, Oughtred played a pivotal role in increasing net revenues from $270M to approximately $10B, scaling its retail footprint from less than 50 stores to over 700, and expanding its international footprint from North America-only to over 25 countries globally.

06:46 EDT Lazard reports preliminary AUM $245B as of May 31 - Lazard reported that its preliminary assets under management as of May 31, 2024 totaled approximately $245B. The month's AUM included market appreciation of $4.4B, net outflows of $1.6B and foreign exchange appreciation of $1.4B.

06:36 EDT Fisker issues two voluntary recalls for vehicles in North America, Europe - Fisker announced that it has issued two voluntary recalls for vehicles in North America and Europe for software-related issues. Fisker is issuing a voluntary safety recall for a total of 11,201 Fisker Oceans across the U.S., Canada, and Europe. As these vehicles' current Motor Control Unit and Vehicle Control Unit software may cause the vehicle to enter a safe state protection mode, potentially leading to a loss of motor power, all affected vehicles will receive an update to version OS 2.1 of Fisker's vehicle software via an over-the-air process. Fisker is also issuing a voluntary noncompliance recall for 6,864 Fisker Oceans in the U.S. and 281 in Canada. As these vehicles do not currently comply with certain Federal Motor Vehicle Safety Standards standards regarding gauges and telltale icons in the cluster display, all affected vehicles will receive an update to version OS 2.1 of Fisker's vehicle software via an OTA process. The National Highway Traffic Safety Administration and Transport Canada are in the process of posting these recall notices on their websites. Vehicles already updated to OS 2.1 are not affected by these recall actions, and Fisker expects to complete the OTA software update process by June 30, 2024. The company informed its dealer partners of these recall actions on May 30, 2024, and will notify owners by June 30, 2024.

06:32 EDT Target increases quarterly dividend 1.8% to $1.12 per share - The board of directors of Target has declared a quarterly dividend of $1.12 per common share, a 1.8% increase from the prior quarterly dividend of $1.10. The dividend is payable September 10 to shareholders of record at the close of business August 21. The third quarter dividend will be the company's 228th consecutive dividend paid since October 1967 when the company became publicly held. With the increase announced, 2024 is on track to be the 53rd consecutive year in which Target has increased its annual dividend.

06:09 EDT 51Talk Online Education sees Q2 gross billings $13.5M-$14M - The company said, "For the second quarter of 2024, the Company currently expects net gross billings to be between $13.5 million and $14.0 million, which would represent a sequential growth of 7.5% to 11.5%. The foregoing outlook is based on current market conditions and reflects the Company's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change."

06:02 EDT TRI Pointe appoints Urmila Menon as Chief Information Officer - Tri Pointe Homes announced the promotion of Linda Mamet to Executive Vice President in addition to her Chief Marketing Officer role, as well as the appointment of Urmila Menon as the company's new Chief Information Officer. In her expanded capacity, Mamet will continue to oversee sales, marketing and business intelligence strategies while also collaborating closely with Menon, IT team members and functional leaders to evolve the company's technological capabilities. Mamet joined Tri Pointe Homes in 2014 as Vice President of Corporate Marketing and is a key member of the executive leadership team that addresses all facets of running the company. Joining Tri Pointe Homes as its new Chief Information Officer, and reporting to Mamet, Menon is a seasoned technology leader with over three decades of experience in technology management, product management, strategic planning, and team leadership. Most recently, she served as Chief Technology Officer of ATI Restoration, a national disaster recovery firm handling building remediation and reconstruction. Menon's career began in software engineering, and she has held several senior technology leadership roles in both B2B and B2C companies, including e-commerce environments.

05:56 EDT Caledonia Mining reports cancellation of block admission in ATM sales agreement - Caledonia Mining announced that it has cancelled its block admission, and that no shares have, or will be, allotted pursuant to its "At the Market" or "ATM" sales agreement with Cantor Fitzgerald & Co, which was announced on May 18, 2023. The company's Form F-3 Registration Statement under the Securities Act of 1933 dated April 26, 2021 and as amended on May 14, 2021, which enabled the company to issue shares under the ATM Sales Agreement, expired on May 18. As a result, the block admission has been cancelled with an effective date of June 12.

05:50 EDT Aon enters $350M insurance program with U.S. International Development Finance - Aon plc announced a $350M insurance program with the U.S. International Development Finance Corporation to build insurance capacity and accelerate new capital investment and economic recovery in Ukraine. As one of the largest global brokers operating in Ukraine, Aon coordinated a $50M reinsurance facility, working closely with DFC and the Ukraine Ministry for Development of Economy and Trade to support the active and ongoing issuance of on-the-ground war risk policies to businesses operating in Ukraine. Aon and DFC collaborated on an additional $300M in war risk insurance specifically designed for Ukraine's health care and agriculture industries.